Your session is about to expire
← Back to Search
Multilevel Interventions for Lung Cancer Screening Adherence (Larch Trial)
N/A
Waitlist Available
Led By Karen Wernli, PhD
Research Sponsored by Kaiser Permanente
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Speak English or Spanish
Aged 50-78 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks after index ldct
Awards & highlights
Larch Trial Summary
This trial aims to improve early detection of lung cancer through patient education & reminders to increase screening adherence.
Who is the study for?
This trial is for individuals aged 50-78 who have had a negative lung screening scan, speak English or Spanish, and meet US Preventive Services Task Force guidelines. They must be members of KPWA. People with previous lung cancer diagnoses or those needing an interpreter other than for Spanish are excluded.Check my eligibility
What is being tested?
The study is examining the effectiveness of patient education combined with stepped reminders to improve adherence to annual lung cancer screenings among eligible participants.See study design
What are the potential side effects?
Since this trial focuses on educational materials and reminder systems rather than medications, there are no direct medical side effects associated with the interventions being tested.
Larch Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I speak English or Spanish.
Select...
I am between 50 and 78 years old.
Larch Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 weeks after index ldct
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks after index ldct
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Rate of repeat annual lung cancer screening
Secondary outcome measures
Attitudes and beliefs
Knowledge of lung cancer screening
Larch Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: Stepped Reminders onlyExperimental Treatment1 Intervention
Prior to patient's next LDCT scan is due, MA begins Stepped Reminders intervention:
MA pends LDCT orders to PCP to sign. MA sends reminders to patient when order is placed and follows up by phone if patient has not scheduled LDCT.
Group II: Patient Video onlyExperimental Treatment1 Intervention
About 3 weeks after the index LDCT, the study Medical Assistant (MA) will deliver a link to the Patient Voices Video, an educational video about lung cancer screening.
Group III: Patient Video and Stepped RemindersExperimental Treatment2 Interventions
See above. Those assigned to the Patient Video and Stepped Reminders will receive both interventions, as described above.
Group IV: Usual CareActive Control1 Intervention
Those assigned to the the Usual Care arm will continue to receive usual lung cancer screening care.
Find a Location
Who is running the clinical trial?
Kaiser PermanenteLead Sponsor
538 Previous Clinical Trials
24,111,487 Total Patients Enrolled
Fred Hutchinson Cancer CenterOTHER
557 Previous Clinical Trials
1,341,909 Total Patients Enrolled
Hackensack Meridian HealthOTHER
131 Previous Clinical Trials
26,638 Total Patients Enrolled
1 Trials studying Lung Cancer Screening
1,114 Patients Enrolled for Lung Cancer Screening
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I speak English or Spanish.You had a recent scan that did not show any signs of lung cancer.I am between 50 and 78 years old.I was previously diagnosed with lung cancer.Patients who have a positive result on a scan.Members of the KPWA.
Research Study Groups:
This trial has the following groups:- Group 1: Usual Care
- Group 2: Patient Video only
- Group 3: Stepped Reminders only
- Group 4: Patient Video and Stepped Reminders
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any ongoing recruitment opportunities for this clinical trial?
"At present, this medical study is not recruiting. The inaugural listing was on December 12th 2022 and the post has since been updated as recently as February 17th 2023. Nevertheless, there are 1592 other clinical trials actively looking for participants right now."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger